Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1352 | Pituitary Basic | ICEECE2012

Effects of the combined treatment with AMPK activator and somatostatin-14 on hormone secretion and cell proliferation in cultured GH-secreting pituitary tumor cells

Tulipano G. , Faggi L. , Losa M. , Mortini P. , Spinello M. , Cocchi D. , Giustina A.

AMP-activated protein kinase (AMPK) activation decreased GH release and intracellular GH storage in rat pituitary cell cultures and reduced cell proliferation in rat pituitary adenomatous cells (GH3) cultures.We investigated the effects of the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) as compared to somatostatin-14 on cell viability (MTT assay after 48-h) and GH secretion (over 24 h) in 16 human GH-secreting pituitary adenomas ...

ea0029p1463 | Pituitary Clinical | ICEECE2012

META-analysis on the effects of octreotide on tumor mass in acromegaly

Mazziotti G , Torri V , Spinello M , Floriani I , Melmed S , Giustina A

The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower GH levels in patients with acromegaly and may also induce pituitary tumor shrinkage. However, inconclusive evidences in this respect have been produced by either single-center research paper or pooled analyses. Therefore, we performed a meta-analysis to thoroughly assess the current literature on the effect of octreotide on pituitary tumor shrinkage. A computerized Medlin...